news
Sandoz acquisition to boost in-house biosimilar capabilities
The proposed transaction means Just-Evotec Biologics’ Toulouse site would be used to develop and manufacture Sandoz biosimilars.
List view / Grid view
Evotec
news
Aurobac Therapeutics launched to fight antimicrobial resistance
Aurobac Therapeutics SAS - a €40m joint venture between Boehringer Ingelheim, Evotec and bioMérieux - has been launched to create the next generation of antimicrobials and diagnostics to fight antimicrobial resistance (AMR).
article
Realising the therapeutic potential of MDMA
Psychedelic drugs are gaining popularity in the pharmaceutical R&D sector because of their apparent benefits for people suffering with neuropsychiatric disorders - and those which are resistant to existing therapies in particular. In this article, Imperial College London’s Professor David Nutt discusses the evidence underlying the development of psychedelic therapies…
news
First AI-designed immuno-oncology drug enters human trials
The A2a receptor antagonist, which aims to inhibit the immunosuppression of T cells by adenosine, was in part designed using Exscientia’s 3D evolutionary artificial intelligence platform.
article
COVID-19: the big repurpose and even bigger pharmaceutical partnership
Heidi West discusses how academia, government and the pharmaceutical industry can work together to potentially repurpose drugs for the treatment of COVID-19.
news
Global collaboration formed to develop novel treatment regimens for TB
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) was devised to create transformative regimens for TB treatment, irrespective of drug resistance status.
